Data mining for censored time-to-event data: A Bayesian network model
  for predicting cardiovascular risk from electronic health record data by Bandyopadhyay, Sunayan et al.
ar
X
iv
:1
40
4.
21
89
v1
  [
sta
t.M
L]
  8
 A
pr
 20
14
Data mining for censored time-to-event data: A Bayesian network
model for predicting cardiovascular risk from electronic health
record data
Sunayan Bandyopadhyay∗, Julian Wolfson†, David M. Vock†,
Gabriela Vazquez-Benitez‡, Gediminas Adomavicius§, Mohamed Elidrisi∗,
Paul E. Johnson§, and Patrick J. O’Connor‡
April 9, 2014
Abstract
Models for predicting the risk of cardiovascular events based on individual patient charac-
teristics are important tools for managing patient care. Most current and commonly used risk
prediction models have been built from carefully selected epidemiological cohorts. However, the
homogeneity and limited size of such cohorts restricts the predictive power and generalizability
of these risk models to other populations. Electronic health data (EHD) from large health care
systems provide access to data on large, heterogeneous, and contemporaneous patient popula-
tions. The unique features and challenges of EHD, including missing risk factor information,
non-linear relationships between risk factors and cardiovascular event outcomes, and differing ef-
fects from different patient subgroups, demand novel machine learning approaches to risk model
development. In this paper, we present a machine learning approach based on Bayesian networks
trained on EHD to predict the probability of having a cardiovascular event within five years. In
such data, event status may be unknown for some individuals as the event time is right-censored
due to disenrollment and incomplete follow-up. Since many traditional data mining methods
are not well-suited for such data, we describe how to modify both modelling and assessment
techniques to account for censored observation times. We show that our approach can lead to
better predictive performance than the Cox proportional hazards model (i.e., a regression-based
approach commonly used for censored, time-to-event data) or a Bayesian network with ad hoc
approaches to right-censoring. Our techniques are motivated by and illustrated on data from a
large U.S. Midwestern health care system.
1 Introduction
In the United States, myocardial infarctions (MI) and strokes are the first and fourth leading causes
of death and, in addition to contributing significantly to mortality, these conditions account for
substantial morbidity with treatment costing more than $300 billion annually [Go et al., 2014].
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Clinical risk prediction scores or algorithms remain important tools for managing patient care
and improving outcomes in the population. Broadly speaking, risk prediction scores can raise
awareness of the substantial burden of cardiovascular disease (CVD) and risk factors associated with
developing CVD [Lloyd-Jones, 2010]. In the clinical setting, accurate personalized cardiovascular
risk prediction may identify patients at high risk for experiencing cardiovascular (CV) events (e.g.,
MI, stroke) so that clinicians may develop an appropriate intervention strategy and patients are
motivated to remain adherent to that strategy.
Recent systematic reviews found that there are over 100 risk models produced between 1999
and 2009 [Cooney et al., 2009, 2010, Matheny et al., 2011] including the well-known Framing-
ham [D’Agostino et al., 2008], SCORE [Conroy et al., 2003], ASSIGN-SCORE [Woodward et al.,
2007], QRISK1 [Hippisley-Cox et al., 2007, 2008a], QRISK2 [Hippisley-Cox et al., 2008b], PRO-
CAM [Assmann et al., 2002], WHO/ISH, and Reynolds Risk Score [Ridker et al., 2007, 2008]. Al-
though there are many risk prediction models for cardiovascular disease, nearly all have been
estimated using data from carefully selected epidemiological cohorts. For example, the Framing-
ham risk score is trained on a data set which excludes patients that have had a previous CV event,
which represents a predominantly Caucasian population, and which includes patients from the late
1960s [D’Agostino et al., 2008]. As a result of estimating the risk of CV events using data from
these homogeneous cohorts, existing risk models are likely to only give accurate predictions for
patients who are well represented in the training data sets. Collins and Altman [2009] provide an
excellent illustration of the poor performance of the Framingham risk equations when applied to a
contemporary population in the United Kingdom. Models constructed from a more diverse cohort
are likely to produce more accurate estimates of CVD risk for a wider range of patients seen in the
primary care clinic.
One source of clinical data is electronic health data (EHD) collected by from a health main-
tenance organization (HMO). These data consist of electronic medical records (EMRs), insurance
claims data, and mortality data obtained from the state government. EHD are increasingly available
within the context of large health care systems and capture the characteristics of a heterogeneous
population receiving care in a contemporary clinical setting. EHD databases typically include
records on hundreds of thousands to millions of individual patients; therefore, a risk prediction
model constructed from EHD could yield more accurate and generalizable risk predictions because
even relatively specific sub-populations (e.g., patients with multiple comorbidities) are likely to be
well-represented in such a large database.
1.1 Challenges of electronic health data
Although the scale and complexity of EHD provide great opportunities to improve cardiovascular
risk prediction for contemporary patient populations, these data also pose serious challenges to
those seeking to mine it, especially in comparison to data collected from epidemiological cohorts.
Here, we briefly describe some of these challenges, all of which are present in the data set we analyze
in Section 4.
Missing data: EMR data are purely observational in the sense that they record individu-
als’ encounters with the health care system, however regular or irregular those encounters may
be. Without a structured schedule for obtaining lab measurements, these measurements may be
obtained sporadically or simply be unavailable. Further, even when individuals do make regular
clinical visits, clinical practice guidelines may recommend against obtaining certain measurements
within particularly low-risk populations. For instance, it is uncommon for individuals under the age
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of 40 to obtain cholesterol measurements as part of a routine checkup. Several statistical techniques
exist for imputing missing data, but the scale and complexity of EMR data make many of these
unappealing.
Subgroup heterogeneity: EHD comprehensively describe diverse, contemporaneous patient
populations. In contrast to a cohort study, patients do not have to satisfy eligibility criteria to
appear in the database. Though in some cases it may make sense to restrict an EHD-based study to
a narrowly defined sub-population (e.g., individuals with diabetes), our goal is to develop methods
which make maximal use of the available data. Hence, the advanced risk prediction methods should
be capable of using the data to automatically identify non-linear relationships between risk factors
and CV events as well as sub-populations where the effects of those factors differ.
Sample size: The enormous sample size afforded by EHD is simultaneously a blessing and a
curse. While there are ample data to support flexible nonparametric risk models, the complexity
of these models is restricted by the ability to train them on hundreds of thousands or millions of
records in a reasonable amount of time.
Incomplete follow-up and censoring: Our motivating data set is drawn from 10 years of
EHD derived from an HMO. However, not all subjects were enrolled in the HMO for the full 10-year
period, either because their first enrollment came after the beginning of this period or because they
terminated insurance coverage (e.g., due to a change in employer) during the period. In this paper,
we seek to estimate the 5-year risk of cardiovascular events. But the occurrence of cardiovascular
events is not recorded in the EMR or in claims data during times when subjects are not enrolled,
and a substantial fraction of subjects (71% in our data) do not have enough follow-up data in the
EMR to ascertain if they experienced a cardiovascular event over a 5-year period. In the language
of statistical survival analysis, such subjects are said to be right-censored.
The standard statistical methods to model the relationship between risk factors and time-to-
event outcomes are the Cox proportional hazards model [Cox, 1972] and, to a lesser extent, the
accelerated failure time model [Buckley and James, 1979]. Although these methods handle censored
outcomes, they do not natively address the first three challenges encountered in EHD. In particular,
the proportional hazards model assumes that the risk factors have a linear relationship with the log
hazard of experiencing a CV event. If the analyst has a priori knowledge that this relationship is
non-linear or differs in certain sub-groups, she may include non-linear transformations of predictors
or interactions between predictors, but this is often based on trial and error. Secondly, standard
software for proportional hazards models removes subjects with any missing features which is a
large percentage for EHD, and, as noted above, imputation methods may be onerous given the
scale and complexity of EHD. Finally, as noted by [Kattan et al., 1998], the proportional hazards
model will show improved fit when additional terms are added in the model and there is no reliable
indication when the model has been over fit.
The first three challenges (missing data, subgroup heterogeneity, and data dimensionality) moti-
vate the use of a sophisticated, flexible, and scalable machine learning technique such as a Bayesian
Network to mine EHD. However, the fourth challenge (incomplete follow-up) is not directly ad-
dressed by usual typical machine learning approaches. In the next section, we discuss the implica-
tions of censoring on the application of machine learning techniques.
1.2 Machine learning with censored outcome data
Many data mining techniques have been developed for the related tasks of classification and class
probability estimation for a binary outcome. These methods have been shown to yield a perfor-
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mance that is superior to traditional regression-based techniques in healthcare-related classification
problems [Song et al., 2004, Colombet et al., 2000], and are more adept at handling the afore-
mentioned characteristics of EHD, including correlation and non-linear relationships between the
features. However, they are not designed for use in circumstances where outcomes may be censored.
Fully supervised machine learning methods assume that the outcome is known for all subjects,
but in our setting the binary outcome (whether or not a patient experiences a cardiovascular event
within 5 years) is undetermined for subjects who are censored, i.e., who do not experience an
event but do not have a full 5 years of follow-up. Simplistic techniques to deal with this issue,
such as discarding censored observations (see, e.g., Larranaga et al. [1997], Sierra and Larranaga
[1998], Blanco et al. [2005]) or treating them as zeroes (non-events), are known to induce bias
in the estimation of class probabilities [Kattan et al., 1998], making typical fully supervised clas-
sification approaches unsuitable. For example, Stajduhar et al. [2009] demonstrated the impact
of unaccounted-for censoring on the construction and performance of Bayesian networks. Semi-
supervised approaches are also generally not applicable since the labeled (non-censored) and unla-
beled (censored) observations are not samples from the same underlying population. Furthermore,
censored observations are not truly ‘unlabeled’ since they carry useful partial information about
the outcome (i.e., that the event outcome did not occur before the subject was censored).
There has been an increasing interest to adapt machine learning techniques to this type of cen-
sored, time-to-event data [Lucas et al., 2004]. As one example, Ishwaran et al. [2008] make use of
specialized random survival forests to analyze right-censored survival data, where a survival score
is associated with every terminal node of the trees in the forest. Inspired by the growing need
and opportunities for machine learning approaches to complex healthcare data-driven problems,
we propose a general-purpose extension of Bayesian networks using inverse probability of censoring
weights (IPCW). The resulting technique properly accounts for censoring while retaining the fea-
tures which make this flexible machine learning approach appealing in the context of EHD. We also
show that traditional evaluation metrics for classification accuracy (e.g., receiver-operating curve,
net reclassification improvement) may be misleading in the presence of censoring, and describe
better alternatives.
2 Bayesian networks for electronic health data
2.1 Why Bayesian networks?
Bayesian networks are especially well-suited to handle the intricacies of risk prediction using EHD.
Compared to support vector machines or neural networks, Bayesian networks have a clear edge in
interpretability, which is important to the end-users of these prediction models in the healthcare
domain (e.g., physicians and clinical researchers). The Bayesian network framework we adopt
handles missing data naturally and efficiently, eliminating the need for electronic health data sets
to be “pre-imputed” to produce complete data, and is also computationally efficient.
Because of their interpretability and their ability to aid in reasoning with uncertainty, Bayesian
networks have been used extensively in biomedical applications (see Lucas et al. [2004] for a review).
In particular, they have been used to aid in understanding of disease prognosis and clinical pre-
diction [Andreassen et al., 1999, Verduijn et al., 2007, Lipsky and Lewis, 2005, Sarkar and Koehler,
2013, Vila-Frances et al., 2013, Lappenschaar et al., 2013]; used to guide the selection of the appro-
priate treatment [Lucas et al., 2000, Kazmierska and Malicki, 2008, Smith et al., 2009, Yet et al.,
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2013, Velikova et al., 2014]; and implemented as part of clinical decision support systems [Lucas et al.,
1998, Sesen et al., 2013].
In spite of the wide applicability in biomedical applications, there is a limited amount of pre-
vious work on the application of Bayesian networks to censored outcome data [Lucas et al., 2004].
Zupan et al. [1999] and Stajduhar and Dalbelo-Basic [2010] have proposed approaches in which
censored observations are repeated twice in the dataset, one as experiencing the event and one
event-free. Each of these observations are assigned a weight based on the marginal probability
of experiencing an event between the censoring time and τ , the time the event status will be as-
sessed. This approach, although intuitive, is provably biased and inconsistent because the method
to weight each of the replicated observations is based on the marginal probability and does not
properly account for the covariates. Stajduhar and Dalbelo-Basic [2012] adopt a more principled
likelihood-based approach to imputing event times, but their imputation technique may perform
poorly if the assumed parametric distribution of event times is incorrect. Other approaches, in-
cluding replacing the time-to-event with the martingale from the null model, have been proposed
to handle censored data in other machine learning methods including support vector regression, re-
cursive partitioning, and multiple adaptive regression splines [Therneau et al., 1990, Kattan et al.,
1998, Kattan, 2003]. However, these approaches require that the technique to mine the data per-
mit a continuous outcome and are, therefore, not amenable to the Bayesian network approach
considered here.
In the following, we develop an extension of Bayesian networks which accounts for right-censored
event indicators using inverse probability of censoring weights (IPCW) [Robins and Finkelstein,
2000, Bang and Tsiatis, 2000, 2002, Rotnitzky and Robines, 2004, Tsiatis, 2006]. We begin by
reviewing a classical Bayesian network approach, operating on a binary indicator of whether or
not each subject experienced an event during the follow-up period. Clinical knowledge is used to
construct a graphical model relating the relevant risk factors to the probability of an event. We
then describe a model-averaging strategy to control model complexity and stabilize risk predictions
for small patient subgroups. The extension of IPCW to Bayesian networks is discussed before we
describe how to extend traditional predictive performance evaluation metrics when outcomes may
be right-censored.
2.2 Bayesian networks
Let the features recorded on a patient be represented by a p-dimensional vector X = (X1 · · ·Xp)
where Xi is the i
th risk factor (some of the factors could be missing for certain patients). Let
E = 1 indicate that an event (e.g., a CV event) occurred for a given patient within τ years of the
beginning of the follow-up period, and E = 0 indicate the absence of such an event in that time
frame. Though our ultimate goal is to handle the case where E is unknown for some patients, for
now we assume that at least τ years of follow-up is available on each patient so that E is fully
observed.
The target of estimation is P (E = 1|X); using Bayes theorem, one can rewrite this probability
as
P (E = 1|X) =
P (X|E = 1)P (E = 1)∑
e∈{0,1} P (X|E = e)P (E = e)
, (1)
so that the focus is shifted to estimation of P (X|E = e) and P (E = e) for e = 0, 1. In general,
dimensionality p may be too large to make joint modeling of P (X|E = 1) feasible. To simplify the
5
joint modeling task, one can represent the joint distributions of X|E = e using a directed acyclic
graph (DAG), i.e., a Bayesian network. The DAG encodes conditional independence relationships
between variables, allowing the joint distribution to be decomposed into a product of individual
terms conditioned on their parent variables [Stuart and Peter, 2003]:
P (X |E) =
p∏
i=1
P (Xi|Pa(Xi), E) (2)
where Pa(Xi) are the parents of Xi.
One advantage of the Bayesian network approach is that clinical knowledge can be used to
suggest and refine DAG structures. While methods exist to infer the DAG structure from data, in
our application we used parsimonious DAGs based on information from the medical literature as
well as clinical judgment from the medical experts who collaborated on this research project. The
DAG structure used in our predictive models is shown in Figure 1 (see the caption of the figure for
a brief description) and is explained in greater detail in Section 3. The graphical model in Figure 1
contains both continuous-valued nodes (which are elliptical in the figure) and discrete-valued nodes
(which are rectangular). The network is therefore a hybrid Bayesian network [Murphy, 1998].
2.3 Learning Bayesian network parameters
To evaluate the joint distributions P (X |E = e), for each feature Xi (or group of features modelled
jointly such as the lipid measures in our DAG) we construct vectors Gi such thatGi = (Xi,Pa(Xi))
and learn the joint distributions P (Gi|E) of each of the groups. The conditional distributions
P (Xi|Pa(Xi), E) of Equation (2) can be derived from these joint distributions. This approach
differs slightly from the conventional strategy where a regression model is constructed to link the
values of the parent nodes of Xi to the mean of Xi. Typically, we would assume that the mean of Xi
is linearly related to the values of the parent nodes, and we must learn or estimate the parameters
in this linear regression model. Our approach provides more modeling flexibility (because we do not
have to specify a regression model) without a substantial increase in computation due to our DAG
structure where continuous nodes are arranged in relatively small, mutually independent groupings.
When all the components in Gi are discrete variables, then evaluating the probability distribu-
tions P (Gi|E) is simply a matter of estimating the frequency of each unique state of Gi for E = 0
or E = 1. P (Gi|E) is represented as a probability distribution table of length 2× |Gi|, where |Gi|
is the number of possible unique states of Gi.
Let CGi be the dimension of Gi. When the CGi components in Gi are continuous, the joint
distribution fGi (given E = e) is modelled as a mixture of M multivariate normal distributions, as
follows:
fGi(g|E = e) =
M∑
m=1
ρm,eφ
(
Σ−1m,e(g − µm,e)
)
, (3)
where φ is the density function of a CGi-variate standard normal random variable, µm,e and Σm,e
are the mean vector and variance matrix of Gi, and ρm,e are the mixing parameters. The number
of parameters to estimate is 2×M × CGi(1 + (CGi + 1)/2).
When Gi contains discrete parents (discrete children are not considered in our application), the
components in Gi are partitioned into (Yi,Zi) where Y i represents the CYi continuous risk factors
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Figure 1: The graphical model for our Bayesian network for CV risk prediction. The figure includes
the structure of risk factors, conditioned on the CV event status. In particular, nodes represent
input variables and edges represent conditional dependencies between the variables. The reader
should also assume that our outcome variable (CV Event) is connected to every node in the graph
(omitted in the picture for parsimony). Continuous and discrete variables are indicated by elliptical
and rectangular nodes, respectively. Nodes in boxes with rounded corners indicate that they are
modelled jointly. The nodes are grouped into subgraphs indicated by the dashed boxes. The
grey edge between subgraphs indicates an edge from every node in the source subgraph to every
node in the destination subgraph or node. The full description of each of the features appears in
Section 3. Comorbidity: Whether or not patient has pre-existing CVD; Smoke: current smoking
status of patient; BMI: body mass index of patient; SBP: systolic blood pressure; SBP Med:
Number of blood pressure medication classes currently prescribed to patient; TRG: triglycerides;
HDL: high density lipoprotein; LDL: low density lipoprotein; (TRG, HDL, and LDL are components
of patient’s cholesterol measurement and are modelled jointly); LDL Med: indicator for whether
the patient is on LDL lowering medication.
and Zi the CZi discrete risk factors. The continuous components Yi are then estimated using the
same mixture approach as in Equation (3), conditional on the levels of Zi:
fY i(y|Zi = z,E = e) =
M∑
m=1
ρm,e,zφ
(
Σ−1m,e,z(y − µm,e,z)
)
. (4)
If each component Zki of Zi has Q
k
i possible states, then |Zi| =
∏pzi
k=1Q
k
i . The resulting number
of parameters to estimate is 2×M × |Zi| × CYi(1 + (CYi + 1)/2).
For a fixed number of mixing components M , a standard expectation maximization (EM)
algorithm is used to solve for the maximum likelihood estimators of the mean, variance, and mixing
parameters. In general, in order to control overfitting, one could consider M to be a tunable
parameter and select the number of mixture components using the Bayes Information Criteria
(BIC) or some other goodness-of-fit measure. In the following section, we describe a model averaging
procedure to combine results across multiple values of M .
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2.4 Model averaging
Increasing the number of mixture components in our models can lead to overfitting the training data.
This is even more likely when we try to model distributions that are represented by small subgroups
of patients. We can prevent overfitting by evaluating the weighted average of the predictions of
multiple models of varying complexity trained on samples drawn from the data. The weights are
derived from the BIC, which penalizes complexity of the model, and are approximations to the
posterior probability of the model [Jackson et al., 2009]. Although model averaging has been used
to average over different network structures in Bayesian networks [Tian et al., 2010], to the best of
our knowledge it has not been previously used to average over models of varying complexity within
a single network structure.
To implement the model averaging, we take T bootstrap samples from our training data. For
each bootstrap sample, we fit models with q = 1, . . . , Q mixture components. In our analysis of
cardiovascular risk, we take Q = 4. Generally, Q should be large enough so that the largest values
of Q do not receive much weight. The weights for each level of model complexity q are computed
as follows:
wq =
exp(−0.5Bq)∑
Q exp(−0.5Bq)
, (5)
where Bq =
1
T
∑T
j=1Bq,j and Bq,j is the BIC of the model fit on the j
th bootstrap sample with q
mixtures. The BIC is computed as −2 log(L) + k log(n) where L is the log likelihood evaluated at
the maximum likelihood parameter estimates, n is the number of subjects included in the training
set, and k the number of (free) parameters included in the model.
The probability distribution of an ensemble is simply evaluated by finding the weighted mean
of the probability of each mixture model in the ensemble:
P (X |E;θ,ρ) =
∑
1≤q≤Q
wq

 1
T
∑
1≤t≤T

 ∑
1≤i≤q
ρiP (X |E;θq,t,i)



 , (6)
where θq,t,i is the set of model parameters to be estimated.
2.5 Extension to censored time-to-event data
Our development thus far has assumed that the presence or absence of a CV event E is fully
observed for all patients in the data set, but this is unlikely to be true when using information from
real-world EHD. In this section, we show how it is possible to use a Bayesian network to predict the
risk of a CV event in τ years when the event status at τ years cannot be assessed in some patients
due to right-censoring. More specifically, in our application, once a patient leaves the health system
or the study ends, their health state (i.e., risk factors - covariates of the risk prediction model) and
event history are no longer recorded in the EMR. That is, the patient’s follow-up ends when the
subject leaves the health system. Define T as the time between the beginning of the follow-up
period and a CV event, and define C as the time between the beginning of the follow-up period and
disenrollment or the end of the data capture period. We observe V = min(T,C) and δ = I(T < C),
the indicator for whether or not a CV event occurs. If δ = 0, the subject’s event time is said to be
censored. We can only ascertain the value of E if δ = 1, or δ = 0 and V > τ .
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As mentioned earlier, one naive approach to handle these subjects for whom we cannot ascertain
the value of E would be to exclude them from our training data set or to set E = 0, but both
approaches would lead to biased estimators of the CV risk. Instead we propose to adjust for right-
censoring using an inverse probability of censoring weighting (IPCW) approach. This approach
to handling censored event times assuming that the censoring time C is independent of the CV
event time T and all features X. In our study, most patients are censored due to the end of the
study or because they disenroll from the HMO due to a change in employment. The assumption
is reasonable because the follow-up for most patients ends for reasons unrelated cardiovascular
health. Let G(t) = P (C > t) be the probability that the censoring time is greater than t. We can
estimate G(t) = P (C > t), using the Kaplan-Meier estimator of the survival distribution (i.e., 1
minus the cumulative distribution function) of the censoring times. The Kaplan-Meier estimator
[Kalbfleisch and Prentice, 2002] of the censoring process is given by
Gˆ(t) =
∏
i:ti<t
(
ni − d
∗
i
ni
)
, (7)
where d∗i are the number of subjects who were censored at time ti and ni are the number of subjects
“at risk” (i.e., number of subjects not previously censored or experiencing a CV event) at time ti.
Unlike other ad hoc approaches to handling censored observations, the Kaplan-Meier (or product-
limit) estimator is consistent (i.e., asymptotically unbiased) and efficient even in the presence of
censored observations [Kalbfleisch and Prentice, 2002].
Then, for each patient i, we define a weight
ωi =
{
0 if δi = 0 and Vi < τ
1
Gˆ(min(Vi,τ))
otherwise
To fit the Bayesian network using IPCW, estimation of the parameters in (6) is carried out using a
weighted version of the EM algorithm described above, where the contribution of the ith subject to
the likelihood is weighted by ωi. Details of the weighted EM algorithm are provided in Fraley et al.
[2012]. The weights are computed on the full training sample, and are not re-estimated for each
bootstrap sample. Many software packages implementing the EM algorithm (e.g., Matlab, R) allow
weights to be provided as arguments to the EM function, making the IPCW Bayesian network
approach straightforward to implement.
In the IPCW approach, only those patients for whom we can determine E contribute to the
analysis, but they are reweighted to accurately “represent” the patients who were censored prior
to τ and were, therefore, omitted from the analysis. For example, patients that have a longer time-
to-event are more likely to be censored (G is smaller) and hence receive larger weights. Note that
for subjects with E = 0 (and V > τ) the weights for all individuals are 1/Gˆ(τ) so the maximum
likelihood estimators for P (Gi|Ei = 0) are the same as in the unweighted analysis.
2.6 Obtaining predictions
To obtain the prediction P (E = 1|X), we need to evaluate the right-hand side of Equation (1),
where P (X|E) is given by the product in Equation (2). As noted above, the joint modeling
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described in Section 2.3 yields conditional distributions via the expression
P (Xi|Pa(Xi), E) = P (Xi|Gi \Xi, E)
=
P (Gi|E)
P (Gi \Xi|E)
, (8)
whereGi\Xi are the components of the vectorGi not included inXi. WhenXi is discrete (implying
thatGi contains only discrete nodes), the terms in Equation (8) are derived from a probability table
summarizing the distribution of Gi, given E. When Xi is continuous, the densities are computed
by plugging the estimated mean, variance matrix, and mixing parameters into Equation (6).
2.6.1 Missing features
Within EHD, it is relatively common for attributes to be unmeasured on certain patients; for
example, cholesterol measurements are typically not available on patients under the age of 40. If Xi
is missing, then the corresponding product term from Equation (1) is dropped. When any attribute
from Pa(Xi) is missing (say Ai), we implicitly marginalize over Ai by computing P (Gi \ Ai|E) =∫
a
P (Gi|Ai = a,E)dPAi(a|E) where PAi(a|E) is estimated from subjects with Ai observed. In our
data, information regarding medications, gender, and comorbidity is never missing; therefore, we
are concerned only about marginalizing the continuous part of the distribution.
2.7 Performance evaluation metrics
The challenge of machine learning for censored data extends beyond improving existing methods to
handle censoring. As we discuss in this section, the usual performance metrics applied to classifica-
tion and prediction problems can be misleading when outcomes are subject to censoring. Here, we
present generalizations of standard calibration (goodness-of-fit) and discrimination (concordance-
index and net reclassification improvement) metrics which properly account for censored data and
allow model performance to be assessed more accurately.
2.7.1 Calibration
For standard binary classification problems, calibration is commonly assessed by ranking the pre-
dicted class probabilities for the test set, binning the ranked predictions (e.g., by decile), and
comparing the mean (or median) predicted class probability in each bin to the empirical class
probability of the instances in that bin. We adopt a similar approach here, except that the em-
pirical probability of experiencing an event prior to time τ within each bin is computed via the
Kaplan-Meier estimator to properly account for censoring. Calibration plots compare predicted
and Kaplan-Meier probabilities of experiencing an event before τ within bins defined by ranges of
predicted probabilities. We also compute a calibration statistic,
K =
B∑
j=1
(p¯j − p
KM
j )
2
p¯j(1− p¯j)
where B is the number of bins, p¯j is the average of predicted probabilities in bin j, and p
KM
j
is the Kaplan-Meier estimate of experiencing an event before t, computed form the data in bin
j. K is analogous to the χ2 statistic for assessing the calibration of logistic models suggested by
[Hosmer and Lemeshow, 1980, Lemeshow and Hosmer, 1982].
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2.7.2 Concordance index
The area under the ROC curve (AUC) is a widely used summary measure of predictive model
performance in many disciplines, including medicine. However, for the same reasons that standard
classification techniques fail on censored outcomes, the AUC can also be misleading. Hence, we
propose to employ a generalization of the AUC, the concordance index (C-index) for censored data.
In the absence of censoring, the C-index and AUC coincide; however, the C-index is more easily
adapted to account for censoring.
As described in Harrell [2001], the C-index adapted for censoring considers the concordance
of survival outcomes versus predicted survival probability among pairs of subjects whose survival
outcomes can be ordered; namely, among pairs where both subjects are observed to experience a
CV event, or one subject is observed to experience a CV event before the other subject is censored.
Pairs in which both subjects are censored or in which the censoring time of one precedes the failure
of the other do not contribute to this metric. Let Pˆi(E|X) be the estimated probability that the
ith subject experiences an event within τ years. The the C-index is given by
Ccens(τ) =
∑
i 6=j δiI[Vi < Vj]I[Pˆi(E|X) < Pˆj(E|X)]∑
i 6=j δiI[Vi < Vj]
(9)
Note that the only pairs which contribute to Ccens(τ) are those where one subject experiences
an event prior to τ and the other is known not to have experienced an event before the first subject.
2.7.3 Net Reclassification Improvement
The C-index may be inadequate to distinguish between models that differ in relatively modest
but clinically important ways [Pencina et al., 2008]. Therefore, in addition to the C-index, we
also evaluate the performance of our models using the Net Reclassification Improvement (NRI)
metric [Pencina et al., 2008], which allows the incorporation of relevant domain knowledge into the
performance evaluation process. As with the other metrics presented in this section, the NRI must
be adapted to handle censored outcomes.
The NRI compares the number of “wins” for two models among discordant predictions. It
has been argued that NRI is a particularly relevant measure of comparison between models in
the clinical domain, where it is often more important to discriminate between lower and higher
risk patients than to estimate their risk precisely. Briefly, the NRI is computed by cross-tabulating
predictions from two different models with table cells defined by clinically meaningful cardiovascular
risk categories or bins, then comparing the agreement of discordant predictions with actual event
status. Formally, the NRI for comparing prediction models M1 and M2 using fully observed (i.e.,
not censored) binary event data is given by:
NRI(M1,M2) =
E↑M1 − E
↑
M2
nE
+
E¯↓M1 − E¯
↓
M2
nE¯
(10)
Here E↑M1 is the number of individuals who experienced events and were placed in a higher
risk category by M1 than M2 (i.e., a number of “wins” for M1 over M2 among patients who had
events), and the opposite change in risk categorization yields E↑M2). Similarly, E¯
↓
M1
and E¯↓M2 count
the number of individuals who did not experience an event and were “down-classified” by M1 and
M2, respectively (i.e., “wins” among patients who did not have events). Also, nE and nE¯ are the
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Table 1: Net Reclassification Improvement computation tables for comparing performance of model
M1 vs. model M2.
(a) Reclassification table for people who do not have CV events.
Model M1
Risk high(h) medium(m) low(l)
high(h) Nnhh Nnhm Nnhl
Model M2 medium(m) Nnmh Nnmm Nnml
low(l) Nnlh Nnlm Nnll
(b) Reclassification table for people who have CV events.
Model M1
Risk high(h) medium(m) low(l)
high(h) Nehh Nehm Nehl
Model M2 medium(m) Nemh Nemm Neml
low(l) Nelh Nelm Nell
total number of patients with events and non-events, respectively. A positive NRI(M1,M2) means
better reclassification performance for M1, while a negative NRI(M1,M2) favors M2. While NRIs
can theoretically range from -1 to 1, in the risk prediction setting they do not typically exceed the
range [-0.25, 0.25]. For example, Cook and Ridker [2009] calculated the effects of omitting various
risk factors from the Reynolds Risk Score model for prediction of 10-year cardiovascular risk. The
estimated NRIs ranged from -0.195 (omitting age) to -0.032 (omitting total cholesterol or parental
history of MI), and all were statistically significant at the 0.05 level. In our application, we defined
three risk strata based on clinically relevant cutoffs for the risk of experiencing a cardiovascular
event within 5 years: 0-5% (low risk), 5-10% (moderate risk), and > 10% (high risk); risk predictions
for an individual were considered discordant between two models if the predictions fell in different
ranges.
The predictions that are reclassified from one risk category to another can be represented in two
tables, one for people having events (Table 1b) and one without (Table 1a), where the risk has been
categorized into 3 levels: “high”, “medium”, and “low”. The high, medium, and low categories
for CV risk are usually defined as risk intervals, such as 10-100%, 5-10%, and 0-5%. The entry in
Table 1a, Nnij, means the number of people without events who were classified as belonging to
risk category i by model M2 that were reclassified as belonging to risk category j by model M1.
Similarly, the entry in Table 1b, Neij , means the number of people with events who were classified
as belonging to risk category i by model M2 that were reclassified as belonging to risk category j
by model M1.
For a person with events, a “win” for model M1 over M2 means M1 predicts a higher risk
category for the person than M2. Based on our reclassification table, E
↑
M1
= Nemh+Nelh+Nelm.
Similarly, the number of “wins” M2 has over M1 for people with events is: E
↑
M2
= Nehm +Nehl +
Neml. For people without events, we can write the write the corresponding “wins” from Table 1a
as follows: E¯↓M1 = Nnhm+Nnhl+Nnml and E¯
↓
M2
= Nnmh+Nnlh+Nnlm. nE and nE¯ are the sum
of the entries in Tables 1b and 1a respectively. From the values evaluated using the reclassification
tables, the Net Reclassification improvement is evaluated using Equation (10).
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The NRI statistic cannot be applied directly to data where the outcome status of some subjects
is unknown. In our setting, omitting subjects with less than five years of follow-up (or treating
them as non-events) will result in biased estimates of the NRI. To evaluate risk reclassification on
our test data which are subject to censoring, we use a “censoring-adjusted” NRI (cNRI) due to
Pencina et al. [2011] which takes the form:
cNRI(M1,M2) =
E∗,↑M1 − E
∗,↑
M2
n∗E
+
E¯∗,↓M1 − E¯
∗,↓
M2
n∗
E¯
(11)
where E∗,↑M1 , E
∗,↓
M1
, E∗,↑M2 , E
∗,↓
M2
, n∗E and n
∗
E¯
are analogous to the quantities in (10), but correspond to
expected number of subjects in each category, with the expectations computed using the Kaplan-
Meier estimator to account for censoring. As with the usual NRI, a positive cNRI(M1,M2) means
better reclassification performance for modelM1, while a negative cNRI(M1,M2) favors modelM2.
Uncertainty intervals can be obtained by computing the cNRIs on the test set for predictions fitted
to 500 bootstrap resamples of the training data.
3 Electronic health data and preprocessing
Our study was conducted utilizing the HMO Research Network Virtual Data Warehouse (HMORN
VDW) from a healthcare system from the Midwestern U.S. The VDW stores data in standardized
data structures including insurance enrollment, demographics, pharmaceutical dispensing, utiliza-
tion, vital signs, laboratory, census and death records. These data are obtained from both the EMR
and insurance claims. This health care system includes both an insurance plan and a medical care
network in an open system which is partially overlapping. That is, patients of the insurance plan
may be served by either the internal medical care network and or by external healthcare providers,
and the medical care network serves patients within and outside of the insurance plan. Patient-
members who do not visit any of the clinics and hospitals in-network do not have any medical
information (e.g., blood pressure information) included in the EMR of this system. Furthermore,
once the patient-member disenrolls from the HMO, the patient no longer has any information
recorded in the EMR or insurance claims data.
Study population was initially selected from those enrolled in the insurance plan between 1999
and 2011 and who had at least one outpatient medical encounter at an “in-network” clinic. This
initial selection identified 448,306 subjects.
The goal of our analysis is to develop accurate prediction models of CV risk for patients seen in
the primary clinics of the HMO. Such models will help inform physicians and patients of appropriate
courses of action to take in order to reduce the patient’s likelihood of experiencing a CV event.
In many epidemiological cohorts, patients are screened at a single or small number of visits,
where measurements on all risk factors are collected, and then followed from the final screening visit
to determine if and when they experienced a CV event. However, in clinical practice, patients may
have relevant risk factors recorded over a series of visits to the physician. Therefore, we divided
the EHD on any given patient-member into: (i) a baseline period, where we ascertained the risk
factors, and (ii) a follow-up period, where we assessed whether a patient experienced a CV event
(and, if so, when). The baseline period consisted of the time between the first blood pressure
reading during the enrollment period and the date of the final blood pressure reading at most 1.5
years from the first measurement. This approach balances the competing goals of having a long
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baseline period so that we capture data on as many features as possible and a long follow-up period
to reduce censoring.
The follow-up period for a patient begins at the end of the baseline period and continues until
either the patient experiences a CV event (defined below), or the patient disenrolls from the HMO
for more than 90 days, or the study ends (2011), whichever comes first.
3.1 Inclusion and exclusion criteria
To ensure that we had sufficient time to collect baseline risk factors on subjects, we restricted
the analysis to those subjects with at least one year of continuous insurance enrollment. Some
of the patients were sporadically enrolled during the period of study; however, for the purpose of
our analysis, we ignored gaps in enrollment less than 90 days and considered a patient-member
continuously enrolled over this period (these gaps in enrollment are likely due to administrative
errors or patients changing employers but still electing coverage with the same HMO).
We further restrict our study population to include only patients with two medical encounters in
the in-network clinic with blood pressure information at least 30 days but at most 1.5 years apart,
with drug coverage, and greater than 18 years of age at the end of the baseline period. These
inclusion criteria were implemented because we wanted to predict CV risk among those patients
treated routinely in the primary care clinic. Patients who are only infrequently treated in the
emergency room or urgent care clinics (i.e., settings where patients are unlikely to be counselled
about their CV risk) were not of interest in this analysis.
Finally, in this study we included only non-diabetic patients. Diabetic patients represent a
highly specialized population and would benefit from a specialized risk prediction model that is
targeted specifically to them (such as the UKPDS model [Clarke et al., 2004]), which was beyond
the scope for this specific paper. The inclusion and exclusion criteria are summarized in Figure 2,
and the distribution of the follow-up periods for the resulting analysis cohort is given in Figure 3.
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..Initial cohort (n=448,306). .
Included patients-members:
a) Enrolled between 1999-2011 AND
b) At least one visit to in-network
clinic or hospital
.Exclude 87,557 patients with contin-
uous enrollment less than one year.
.
.
Exclude 160,977 patients without two
blood pressure measurements at least
30 days and at most 1.5 years apart.
.
.Exclude 4,743 patients
without drug coverage.
.
.Exclude 6,269 patients
under 18 years of age.
.
.Exclude 16,186 diabetic patients. .
.Final analysis cohort (n=172,571). .
Figure 2: Flowchart of inclusion and exclusion criteria for analysis
3.2 Risk factor ascertainment
Risk factors incorporated in the Bayesian network include age, gender, systolic blood pressure
(SBP), smoking status, body mass index (BMI), cholesterol-related measurement values (LDL,
HDL, TRG), blood pressure and cholesterol medications, as well as indicators of pre-existing car-
diovascular disease (i.e., pre-existing related diagnoses or procedures). The summary statistics for
the risk factors are given in Table 2. We also provide a brief discussion on how each of the features
and the outcome, CV event, was defined based on information in the EMR and claims data.
Systolic blood pressure (SBP): Calculated as an average of all the blood pressure mea-
surements taken during the baseline period. Blood pressure readings obtained during emergency
department visits, urgent care visits, hospital admission, and during procedures (e.g., surgeries)
were excluded from consideration because they may be influenced by acute conditions.
Body mass index (BMI): Calculated as a function of patient’s height and weight. The height
of an individual is the average height measured at any encounter (possibly outside of the baseline
period). Because all subjects in the analysis dataset are over 18 years of age, we expect height to
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Table 2: Summary measures of the risk factors included in our prediction models in the entire study cohort.
Median (IQR)
Feature Name or % Missing Description
N (%)
Gender
Female 105,234 (60.98) 0
Male 67,337 (39.02) 0
Age (Years) 42.00 (30.00 - 55.00) 0 Age at the end of the baseline period
SBP (mm Hg) 118.00 (110.00 - 128.00) 0 Mean systolic blood pressure during baseline period
BMI (kg/m2) 26.72 (23.60 - 31.06) 10 Body mass index
LDL (mg/dL) 118.00 (96.00 - 142.00) 66 Final low density lipoprotein during baseline period
HDL (mg/dL) 48.00 (39.00 - 58.00) 55 Final high density lipoprotein during baseline period
TRG (mg/dL) 108.00 (77.00 - 158.00) 66 Final tryglyceride during baseline period
Smoking Smoking status in EMR
Never or Passive 126,463 (73.28) 0
Quit 16,898 (9.79) 0
Current 29,210 (16.93) 0
Comorbidity Presence of comborbidities related to cardiovascular disease
Yes 14,547 (8.43) 0
No 158,024 (91.57) 0
SBP Meds 0 Number of SBP medication classes filled during baseline period
0 118,685 (68.77) 0
1 20,613 (11.94) 0
2 13,883 ( 8.04) 0
3+ 19,390 (11.24) 0
LDL Meds 0
0 154,972 (89.80) 0 Number of LDL medication classes filled during baseline period
1+ 17,599 (10.20) 0
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Figure 3: Distribution of patient follow-up times, i.e., time from the end of the baseline period
until the patient experiences a CV event, the patient disenrolls from the HMO for more than 90
days, or the study ends, in our entire cohort after applying inclusion and exclusion criteria.
remain relatively constant over the follow-up period. The weight is calculated as an average of all
weight measurements taken during the baseline period.
Low density lipoprotein (LDL), high density lipoprotein (HDL), and triglycerides
(TRG): The most recent laboratory measurements before the end of the baseline period is used for
these lipid measures including low density lipoprotein, high density lipoprotein, and triglycerides.
Smoking status: Information about smoking is complicated by the fact that many individ-
ual’s responses vary considerably over time. In our dataset, there are four categories of smoking
history, never smoked, smoking, quit smoking, and passive (i.e., second-hand) smoking. In our anal-
ysis, a person is considered to have never smoked only if they consistently recorded “no smoking”
throughout their association with the insurance provider. A person who has recorded at least two
“smoking” responses is considered currently smoking. For the purpose of constructing the model
we combine the “passive smoking” and “no smoking” categories.
SBP and LDL medications: In our model, SBP medications are represented as the number
of different medication categories a person is prescribed at the end of the baseline period. In
particular, SBP medication categories included: alpha-blockers, beta-blockers, calcium-blockers,
ace-inhibitors, angiotensin, vasodialator, and diuretics. LDL medications represents an indicator
for whether or not a patient is taking any LDL lowering medications, such as statins and fibrates,
at the end of the baseline period. For our analysis, we ignore information regarding the specific
drug dosages because it is difficult to make comparisons between doses from different variants of
the same drug.
Comorbidities: Comorbidities represent serious pre-existing conditions (diseases) and previ-
ously occurred CV events or procedures (surgeries). The existence of comorbidities significantly
elevate the risk of having a CV event in the future. In our study, we included the presence of any
of the following diagnoses (including a diagnosis of a “history of” these conditions) at any point
before the end of the baseline period: chronic kidney disease, coronary heart disease, cardiovascular
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disease, peripheral artery disease, atrial fibrillation, congestive heart failure, MI, and stroke. As we
discuss below, the diagnosis may be part of the EMR or contained as part of an insurance claim.
The Bayesian model that we consider treats comorbidities as a binary variable.
CV Event (outcome variable): Events are the first recorded stroke, myocardial infarction
(MI), or procedure proximal to stroke or MI (e.g., coronary artery bypass surgery, stent for either
the coronary arteries or carotid artery) after the baseline period. This information is obtained from
diagnosis codes recorded by physicians or inferred from procedures such as bypass surgery or stent
placement performed on an individual. In addition to using procedure and diagnosis codes to infer
if a CV event occurred, we consider a patient to have experienced a CV event if the cause of death
listed on the death certificate included MI or stroke.
We note that the diagnosis and procedure codes used to define CV events and comorbidities
may be part of the EMR or part of claims data (to justify the insurance claim). The implication
of this is that patients do not have to seek care at an in-network hospital following a CV event
to infer that the patient had a CV event. The total number of first CV events recorded within
the follow-up period is 4,504; the Kaplan-Meier 5-year event rate for the entire analysis cohort is
2.61%.
3.3 Determining the structure of the Bayesian network
Figure 1 displays the structure of the Bayesian network that we used to construct our prediction
models. The structure was determined by combining known relationships from the medical litera-
ture with input from our clinical colleagues. For example, SBP is known to depend on age, BMI,
and the number of blood pressure medication classes prescribed [Rockwood and Howlett, 2011];
therefore, age, BMI, and blood pressure medication nodes are represented as parents of SBP nodes
in the DAG. Also, LDL, HDL, triglycerides (TRG), age, and LDL medications are similarly known
to interact [Grover et al., 2003]. In this case, the nodes corresponding to age and LDL medications
are the parents of the lipid nodes, which are modelled jointly.
In some cases, it may be preferable to consider several network structures reflecting plausible
relationships between predictor variables. In the process of developing our approach, we considered
several candidate network structures; within a set of similar candidates, the particular structure
did not have a large impact on prediction performance.
4 Models and evaluation metrics
Our goal is to build risk models from EHD and, in the process, address issues typically encountered
with EHD, such as right-censored outcomes, non-linear and non-monotonic effects of risk factors
on risk of events, and overfitting in subgroups that are represented by relatively few patients. In
the context of estimating the five-year risk of a cardiovascular event using the data described in
Section 3, we sought to compare our approach which trains the Bayesian network in Figure 1
using inverse probability of censoring weights (Section 2.5) and using model averaging (Section 2.4)
to other more traditional Bayesian network approaches as well as other techniques for modeling
censored outcomes. Our approach, which we refer to as Bayes-AC as it includes both model
averaging and censoring weights, allows for non-linear relationships between the risk factors and
outcome, addresses censored outcomes, and protects against overfitting in small subpopulations.
In addition to our main approach, we also considered a more basic Bayesian model using a single
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multivariate normal distribution (Bayes-1C) to model P (Gi|E), i.e., no model averaging, but still
accounting for censored outcomes.
For comparison, we train the Bayesian network using an ad hoc approach for censored observa-
tions in which we excluded patients who did not experience an event and did not have 5-years of
follow-up. This ad hoc approach to censoring was used both when the number of mixture compo-
nents was fixed (Bayes-1 and Bayes-3) and with model averaging (Bayes-A).
In addition to the different variations of the Bayesian network models, we considered a Cox
proportional hazards model (COX) because this model is well-known in the medical community
and well-suited to work with censored data. A drawback of the proportional hazards model is
that it does not automatically allow for non-linear relationships between the risk factors and log
hazard. We chose to parameterize the proportional hazards model using the same approach as
D’Agostino et al. [2008]. One of the limitations in using the Cox proportional hazards model is
that it requires complete data to fit the model and to predict risks, therefore, we have to impute
the missing data. We make use of a k-nearest neighbor based algorithm to impute missing data
[Crookston and Finley, 2008]. The data is conditioned on gender and comorbidity status before
it is imputed. This imputation approach requires at least one of the attributes for a given data
point to be known. In our case, age and SBP are known for all patients; therefore, this method of
imputation can be easily applied.
Brief descriptions of the models that we have used in our analysis are given in Table 3. All
models are trained on 129,428 patients (75% of the entire analysis population) drawn at random
from the cohort. The performance of the model is evaluated based on the risk predictions of the
remaining 43,143 patients. The models are compared based on their calibration (as described in
Section 2.7.1) and discrimination metrics, i.e., the C-index and cNRI (as described in Sections
2.7.2 and 2.7.3). In addition to the calibration and the discrimination metrics, we also plot the
average risk predicted by the model against the observed risk across different patient groups. While
the calibration statistic K helps us compare the models using a single numeric metric, these plots
provide us with more information regarding the calibration of a model for different risk ranges
and the direction of deviation (over- or under-prediction) of the model from the observation. A
perfectly calibrated model would be indicated by a 45 degree line in these plots.
To construct these plots, we bin patients based on their predicted risk and evaluate the Kaplan-
Meier estimate of the 5-year probability of experiencing a CV event. For our plots, the patients
in the test set are partitioned into 5 risk bins with boundaries determined by four equally spaced
points between the 5th and 95th percentile of predicted risk in the test set. Note that the predicted
and the observed risk of the patients in the first and the last bin include people whose predicted risk
is lesser than the 5 percentile and the 95 percentile risk predictions respectively. We also evaluate
the 95% confidence interval of the Kaplan-Meier estimate of the observed risk, represented as error
bars in the plots.
5 Results
The calibration and discrimination of the models, evaluated on the test set, is summarized in
Table 4. Specific comparisons between our approach, which incorporated model averaging and
IPCW to train a Bayesian network, and other more standard modeling approaches are described
in detail below.
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Table 3: Overview of the models considered in the analysis of 5-year cardiovascular event risk.
Model Name Description
Bayesian network models without accounting for censoring
Bayes-1 basic model, using 1 normal distribution for all continuous variables
Bayes-3 more complex model, using mixture of 3 normal distributions for all continuous variables
Bayes-A ensemble approach, using model averaging for models with mixtures of different sizes (1-4 normals)
Bayesian network models accounting for censoring
Bayes-1C Bayes-1 with inverse probability of censoring weights
Bayes-AC Bayes-A with inverse probability of censoring weights
Standard regression-based baseline approach for censored data
COX Cox proportional hazards model
Table 4: Calibration and discrimination of the models described in Table 3, evaluated on the hold-
out test set. Predicted event rate: Average predicted probability of experiencing a CV event within
5 years, the Kaplan-Meier estimate in the test set was 2.61%; Calibration: calibration test statistic
K; C-index: Concordance index; cNRI: net reclassification improvement for censored outcomes.
Predicted event rate (%) Calibration C-index cNRI (%)
(Observed rate: 2.61%) statistic K (compared to COX)
Bayes-1 5.60 0.223 0.837 10.86
Bayes-3 5.34 0.288 0.821 6.76
Bayes-A 5.34 0.186 0.843 10.37
Bayes-1C 2.67 0.011 0.843 8.18
Bayes-AC 2.45 0.012 0.849 8.88
COX 2.12 0.017 0.839 -
5.1 Censoring-unaware Bayesian networks
The Bayesian network models that do not incorporate inverse probability of censoring weighting
discard subjects who do not have a follow-up time of at least 5 years and do not experience an
event, but still include subjects who have events even if they have a follow-up time of less than five
years. As a result, all of these models (Bayes-1, Bayes-3, and Bayes-A) over-predict risk and hence
are poorly calibrated (see Figure 4). This estimation approach leads to a poorly calibrated model
which over-predicts risk significantly. Although the observed 5 year event rate for the test set was
2.61%, the average risk predicted by Bayes-1, Bayes-3, and Bayes-A was 5.60%, 5.34%, and 5.34%,
respectively.
The Bayes-3 model, in which all continuous features are modeled as a mixture of three mul-
tivariate normal distributions, consistently performs worse than the modeling approach with less
flexibility (Bayes-1) across all measures of calibration and discrimination. In contrast, considering
a model-averaged estimate of CV risk, which averages over model complexity using a data-driven
approach, led to improvements in both calibration and discrimination. Specifically, the averaged
model predicts the risk of a CV event better in groups where few events occur. In the sub-population
of patients that are not on blood pressure medications and has an event rate of 0.39% (as compared
to an average event rate of 2.61%), the Bayes-A model has C-index of 0.75 which is significantly
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higher than the C-indices 0.65 and 0.56 for the Bayes-1 and Bayes-3 models, respectively. In sum-
mary, complex model strategies are able to extract more structure from the data but must be
implemented intelligently. The benefit of model averaging is that it allows the analyst to consider
more complex models but these more complex models (with greater number of mixture compo-
nents) are only given substantial weight in Equation 5 if there is enough improvement in the model
fit to justify models with more parameters. As mentioned earlier, we use the BIC as the metric to
balance model complexity and parsimony.
We note briefly that, while these models show a significant improvement in the discrimination
compared to the standard Cox proportional hazards models using cNRI, it is well known that the
NRI statistic can be misleading when one of the models is badly calibrated, such as the models
that do not account for censoring [Pepe, 2011]. The cNRI statistic that we consider weights the
percentage of “wins” for those experiencing an event equally to those not experiencing an event. The
Bayesian network models that do not account for censoring are heavily biased toward predicting
higher risk; therefore, it produces a significant number of “wins” for people who have events.
Therefore, it is most meaningful to use the cNRI metric only when both models being compared
are reasonably well-calibrated.
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Figure 4: Calibration of Bayesian network models without IPCW both with and without model
averaging on the hold-out test set.
5.2 Bayesian networks accounting for censoring using IPCW
Comparing the parsimonious Bayesian networks and model-averaged Bayesian networks that do
and do not incorporate inverse probability of censoring weights (Bayes-1 versus Bayes-1C and
Bayes-A versus Bayes-AC), there is a dramatic improvement in the calibration of those models
which properly account for censoring (Figure 5). In these models, the average predicted event
rates 2.67% (Bayes-1C) and 2.45% (Bayes-AC) is much closer to the observed event rate in the
test set than the equivalent models that are fit ignoring censoring. The calibration statistic is also
much closer to zero, the value we would expect for a perfectly calibrated model. Both Bayes-1C
and Bayes-AC also show slightly improved discrimination compared to the respective models that
do not account for censoring (C-index 0.837 versus 0.843 and 0.843 versus 0.849, respectively).
Considering the cNRI, both of these models are significantly better in terms of discrimination than
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the standard Cox proportional hazards model but, unlike the Bayes-1 and Bayes-A models, do not
sacrifice calibration to improve net reclassification.
Overall, the Bayes-AC model, which uses inverse probability of censoring weights and model
averaging, results in the best performance of all our Bayesian network models. Unlike the Bayes-1
model (a more traditional Bayesian network model), our approach properly accounts for censoring
leading to improved calibration and properly protects against over-fitting leading to improved
discrimination.
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Figure 5: Calibration of censoring-aware vs. censoring-unaware Bayesian network models on the
hold-out test set.
5.3 Censoring-aware Bayesian networks vs. traditional survival analysis
As noted previously, the Cox proportional hazards model (COX) is the standard approach for
data in which the outcome may be right-censored. As compared to this model, our Bayesian
network model (Bayes-AC) provides improvement across all calibration and discrimination metrics
considered for this predictive task. Overall, the average predicted event rate for the Bayes-AC model
(2.48%) was closer to the observed event rate (2.61%) in the test set than the one demonstrated by
COX (2.12%). The C-index of Bayes-AC is 0.849 (versus 0.839 for COX), and the cNRI of Bayes-AC
compared to COX is 8.88%, both of which reflect significant improvement in the discrimination. To
put the reclassification performance in context, this is more than double the improvement that can
be obtained from adding the total cholesterol (or about half the improvement from adding age) into
the COX risk prediction model [Cook and Ridker, 2009]. Our improvement in cNRI can largely be
attributed to the fact that Bayes-AC predicts a higher risk category for substantially more people
with events compared to COX (Tables 5b and 5c). On the other hand, the COX model predicts
a lower risk category for a similar percentage of patients without events as Bayes-AC (Tables 5a
and 5c). More generally, the COX model tends to under-predict the risk of events as compared
to Bayes-AC largely due to its comparatively poorer calibration. Overall, Bayes-AC reclassifies a
higher fraction of people in the correct direction.
Although the overall improvement in calibration was not very large (Figure 6), the Bayesian
network model also allows for greater flexibility to model CV risk in certain subgroups. For example,
it is generally understood that the CV risk rises with increased blood pressure [Stamler et al., 1993].
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Table 5: Censoring-adjusted Net Reclassification Improvement computation tables for comparing
performance of Bayes-AC vs. COX on the hold-out test set.
(a) Reclassification table for patients without CV events.
Bayes-AC
Risk >10% 5-10% 0-5%
>10% 2,091 490 240
COX 5-10% 878 808 1,023
0-5% 307 729 31,058
(b) Reclassification table for patients with CV events.
Bayes-AC
Risk >10% 5-10% 0-5%
>10% 513 52 14
COX 5-10% 121 61 36
0-5% 34 47 196
(c) cNRI computation based on the reclassification tables.
Censoring-adjusted NRI calculation Quantity
Number of patients without events predicted in a lower risk category by Bayes-AC (E¯∗,↓M1) 1,753
Number of patients without events predicted in a lower risk category by COX (E¯∗,↓M2) 1,914
Total number of patients without events (n∗
E¯
) 37,624
Number of patients with events predicted in a higher risk category by Bayes-AC (E∗,↑M1) 202
Number of patients with events predicted in a higher risk category by COX (E∗,↑M2) 102
Total number of patients with events (n∗E) 1,074
Risk reclassification improvement for patients without events -0.0043
Risk reclassification improvement for patients with events 0.0931
Total net risk reclassification improvement 0.0888
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Figure 6: Calibration comparison of the Cox proportional hazards model to the censoring-aware
Bayesian network with model averaging on the hold-out test set.
In most cases, our data supports this assertion. However for males who are already on a blood
pressure medication, the relationship between the risk and blood pressure is not strictly increasing,
as we see in Figure 7. The risk increases with decreasing SBP for SBP below 130 mmHg. This
observation is interesting because physicians typically treat SBP down to 130 mmHg for people
whose blood pressure is not controlled. Blood pressure being treated below 130 mmHg may indicate
an underlying disease which is probably evident to a physician but is not captured by the risk
factors that we have trained our model on. The underlying disease increases the risk for this group
of patients.
The proportional hazards model that we are using forces a linear relationship between the log
hazard and the log of SBP and, thus, ends up modeling the risk well only for people whose blood
pressure is relatively elevated. This is evident in Figure 7 which shows the Bayes-AC model with
better calibration. In addition, the C-index of the Bayes-AC model (0.646) is significantly higher
that of the COX model (0.576) for predictions in this subgroup.
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Figure 7: Relationship between systolic blood pressure and CV risk for males who are on SBP
medication.
24
6 Discussion and conclusion
This paper focuses on the application of a machine learning approach to risk prediction using
EHD, when event times may be censored due to unequal individual follow-up. Traditional statistical
models for event-time data with censored observations are well-developed, but typically less flexible
than established machine learning techniques for classification. On the other hand, most classifiers
do not handle censoring, as they assume that labels in the training data are fully observed (or in the
case of a semi-supervised classifier, observed on a random subsample of individuals). Our proposed
technique combines features from both of these approaches, using inverse probability weighting to
extend the Bayesian network technique for censored event data. Although we apply our approach
to a Bayesian network, IPCW can be extended to other machine learning classifiers.
In addition to offering both modeling flexibility and statistical validity, our technique seam-
lessly handles missing data, which is common in EHD, and offers the opportunity to combine
findings from the medical literature with clinical judgment to shape the model. The advantages
of our method are illustrated by applying it to a large electronic health database. We show that:
(1) ignoring censoring when performing classification results in grossly mis-calibrated predictions,
(2) the Bayesian network learns non-linear predictor-outcome relationships better than standard
proportional hazards regression models of the type typically used to construct cardiovascular risk
models from longitudinal studies with censored event data.
In addition to presenting a novel method, we also emphasize the importance of using appropriate
criteria for assessing the performance of predictive models for censored data. Commonly-employed
metrics for calibration and discrimination require event indicators which are fully known, and can
be misleading in the presence of censoring. We present alternate metrics which are tailored to the
censored data setting.
As we noted previously, the use of inverse probability of censoring weighting relies on the
assumption that the censoring time is independent of the CV event time. Heuristically, we assume
that patients more or less likely to have a CV event are not more likely to disenroll from the health
system. We could relax this assumption by modeling the censoring time as a function of the risk
factors.
Though there are known techniques for searching across multiple DAG structures in the context
of Bayesian networks, we chose to focus on techniques for learning parameters for a given, fixed
network. This decision was motivated by the fact that our clinical collaborators desire model
interpretability and face validity, which may not be achieved with an automated process determining
network topology. Further, flexible methods such as Bayesian networks are prone to overfitting. We
control overfitting in our method by implementing BIC model averaging and bootstrapping; in our
experiments, the method was not highly sensitive to tuning parameter values which determined the
maximum number of mixture components in each model and the number of bootstrap resamples,
provided these were set within reasonable ranges (> 3 and > 10, respectively).
Though motivated by an example in electronic health data, our technique is applicable to any
situation where event outcomes are subject to censoring. For example, in economics, one might
wish to predict whether recently-unemployed individuals will be re-hired within a fixed time period,
an outcome which is likely to be censored in most feasible study designs. In our context, we plan to
incorporate this technique into a point-of-care clinical decision support system, which will provide
more accurate cardiovascular risk predictions for patients based on their individual health history.
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